ACST Acasti Pharma Inc.

0.95
-0.01  -1%
Previous Close 0.95
Open 0.93
Price To Book 3.19
Market Cap 73843247
Shares 78,132,734
Volume 175,845
Short Ratio
Av. Daily Volume 310,160

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due in December 2019.
CaPre (TRILOGY trial)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
  2. Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
  3. Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
  4. Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
  5. Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50
  6. Acasti: Fiscal 3Q Earnings Snapshot
  7. Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
  8. Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
  9. 4 Healthcare Stocks Looking To Set January Highs
  10. Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
  11. Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
  12. Generic Industry on Path to Recovery: 3 Hot Picks for 2019
  13. Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
  14. Acasti Pharma to Present at the 11th Annual LD Micro Main Event
  15. Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
  16. Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
  17. Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review